PharmiNews

The Directory of Pharma Companies and News

Norgine

Norgine logo
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine’s total revenue was €296 million and the company employs over 1,000 people. Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth. Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
Category:
Category:

Norgine News

DateNews
2016-10-31UK STUDY SHOWS RIFAXIMIN-α (XIFAXAN® 550mg / TARGAXAN®550mg) FOR HEPATIC ENCEPHALOPATHY MAY REDUCE COSTS TO HEALTHCAR...
2016-10-19POSITIVE US PHASE III DATA SHOW EFFICACY OF PLENVUâ„¢ (NER1006), A LOW VOLUME, PEG BASED BOWEL CLEANSING SOLUTION
2015-11-19TWO NEW ANALYSES SHOW COST EFFECTIVENESS OF RIFAXIMIN-α 550MG TREATMENT IN BELGIAN AND DUTCH PATIENTS WITH RECURRENT HE...
2015-11-17NORGINE OPENS NEW £4.5 MILLION TEMPERATURE CONTROLLED WAREHOUSE IN HENGOED, WALES
2015-11-11NEW GERMAN DATA SHOW THE USE OF ENDOCUFF VISION® MAY IMPROVE ADENOMA DETECTION RATES AND REDUCE HEALTH SYSTEM COSTS
2015-10-27NORGINE PRESENTS PHASE III STUDY DESIGN FOR NER1006, ITS LOW-VOLUME BOWEL CLEANSING SOLUTION, AT UNITED EUROPEAN GASTROE...
2015-10-20NORGINE TO PRESENT NEW DATA AT UNITED EUROPEAN GASTROENTEROLOGY WEEK 2015
2015-10-12EUROPEAN LIVER PATIENTS’ ASSOCIATION (ELPA) LAUNCHES CALL TO ACTION REPORT FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY
2015-10-09POSITIVE PHASE III TOP LINE RESULTS DEMONSTRATE EFFICACY OF NER1006, A NOVEL, LOW VOLUME BOWEL PREPARATION, VS. TRISULFA...
2015-09-30NORGINE COMPLETES AGREEMENT WITH ASPEN FOR ITS SOUTHERN AFRICAN OPERATIONS AND PRODUCT RIGHTS
2015-09-28CALL TO ACTION TO IMPROVE DETECTION AND MANAGEMENT OF HEPATIC ENCEPHALOPATHY IN EUROPE
2015-09-01THE NATIONAL HEALTH AUTHORITY BUNDESAMT FÜR GESUNDHEIT APPROVES REIMBURSEMENT OF XIFAXAN® 550 IN SWITZERLAND
2015-06-29NEW DATA SHOW DISCONNECT BETWEEN HEALTHCARE PROFESSIONALS AND PATIENT PERCEPTIONS OF THE IMPACT OF CHEMOTHERAPY- AND RAD...
2015-06-25NORGINE PARTNERS WITH APHARM TO COMMERCIALISE ZIVERELâ„¢ IN SPAIN, AUSTRALIA AND NEW ZEALAND
2015-05-18NEW DATA SHOW ENDOCUFF VISIONâ„¢ IMPROVES OVERALL PERFORMANCE IN COLONOSCOPY AND INCREASES ADENOMA DETECTION RATE
2015-04-22NORGINE PRESENTS PROSPER STUDY - FIRST EVER REAL WORLD EVIDENCE STUDY IN HEPATIC ENCEPHALOPATHY PATIENTS TAKING RIFAXIMI...
2015-04-08NORGINE OBTAINS US PATENT FOR IMPROVED COLON CLEANSING FORMULATIONS
2015-04-01NORGINE COMPLETES ACQUISITION OF A MAJORITY STAKE IN ARC MEDICAL DESIGN
2015-03-17FIRST EVER UK SURVEY OF PATIENT EXPERIENCES WITH HEPATIC ENCEPHALOPATHY SHOWS THE NEED TO IMPROVE DIAGNOSIS AND THE NEED...
2015-03-12NORGINE AND ARC MEDICAL ANNOUNCE PARTNERSHIP FOR ENDOSCOPIC DEVICE, ENDOCUFF VISIONâ„¢
2015-03-05NORGINE AND NAVIDEA ENTER A EUROPEAN PARTNERSHIP FOR LYMPHOSEEK®
2015-02-19NICE GIVES GREEN LIGHT TO TARGAXAN®▼ 550 IN ENGLAND & WALES
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.